PRF Technologies (PRFX) Share-based Compensation (2020 - 2024)
PRF Technologies' (PRFX) quarterly Share-based Compensation came in at -$113000.0 in Q2 2024, down 143.3% YoY from $261000.0 in Q3 2023, and down 198.26% on a QoQ basis from $115000.0 in Q1 2024.
PRF Technologies (PRFX) Share-based Compensation (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has 5 years of Share-based Compensation data on file, last reported at -$113000.0 in Q2 2024.
- Quarterly Share-based Compensation fell 143.3% year-over-year to -$113000.0 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $365000.0 (down 73.93% YoY) and the FY2025 annual result came in at $447000.0, up 44.19% from the prior year.
- Share-based Compensation eased to -$113000.0 in Q2 2024, from $115000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $736000.0 in Q4 2022 to a low of -$113000.0 in Q2 2024.
- A 5-year average of $169166.7 and a median of $181500.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation surged 7566.67% — and 2024, when it plunged 143.3%.
- Tracing PRFX's Share-based Compensation over 5 years: stood at $3000.0 in 2020, then surged by 7566.67% to $230000.0 in 2021, then jumped by 220.0% to $736000.0 in 2022, then plunged by 75.41% to $181000.0 in 2023, then plunged by 162.43% to -$113000.0 in 2024.
- The last three Share-based Compensation figures came in at -$113000.0 (Q2 2024), $115000.0 (Q1 2024), and $181000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.36 Bn | 43.40 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.73 Bn | 40.08 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 32.52 Bn | 30.84 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.14 Bn | 19.48 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.93 Bn | 18.04 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 12.00 Bn | 11.47 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.15 Bn | 9.98 Bn | - | - |
| 10 | PRF Technologies | 647,973.00 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Jun 30, 2024 | -113,000.00 |
| Jun 30, 2024 | -113,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Sep 30, 2023 | 182,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Jun 30, 2023 | 261,000.00 |
| Mar 31, 2023 | 180,000.00 |
| Mar 31, 2023 | 180,000.00 |
| Dec 31, 2022 | 736,000.00 |
| Dec 31, 2022 | 736,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 220,000.00 |
| Jun 30, 2022 | 220,000.00 |